Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,144
archived clinical trials in
Ocular

Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated:  12/31/1969
Retina Institute of Virginia
mi
from
Richmond, VA
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Retina Institute of Virginia
mi
from
Richmond, VA
Click here to add this to my saved trials
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated:  12/31/1969
Virginia Retina Center
mi
from
Warrenton, VA
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Virginia Retina Center
mi
from
Warrenton, VA
Click here to add this to my saved trials
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated:  12/31/1969
Vitreoretinal Associates of Washington
mi
from
Bellevue, WA
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Vitreoretinal Associates of Washington
mi
from
Bellevue, WA
Click here to add this to my saved trials
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated:  12/31/1969
Retina Center Northwest
mi
from
Silverdale, WA
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Retina Center Northwest
mi
from
Silverdale, WA
Click here to add this to my saved trials
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated:  12/31/1969
Spokane Eye Clinical Research
mi
from
Spokane, WA
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Spokane Eye Clinical Research
mi
from
Spokane, WA
Click here to add this to my saved trials
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated:  12/31/1969
West Virginia University Eye Institute
mi
from
Morgantown, WV
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
West Virginia University Eye Institute
mi
from
Morgantown, WV
Click here to add this to my saved trials
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin
mi
from
Madison, WI
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated:  12/31/1969
Specialty Eye Institute
mi
from
Jackson, MI
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Specialty Eye Institute
mi
from
Jackson, MI
Click here to add this to my saved trials
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated:  12/31/1969
Retina Associates, PA
mi
from
Shawnee Mission, KA
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Retina Associates, PA
mi
from
Shawnee Mission, KA
Click here to add this to my saved trials
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated:  12/31/1969
Palmetto Retina Center, LLC
mi
from
Florence, SC
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Palmetto Retina Center, LLC
mi
from
Florence, SC
Click here to add this to my saved trials
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated:  12/31/1969
Eyeclinic Albury Wodonga
mi
from
Albury,
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Eyeclinic Albury Wodonga
mi
from
Albury,
Click here to add this to my saved trials
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated:  12/31/1969
Georgia Retina, P.C.
mi
from
Marietta, GA
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Georgia Retina, P.C.
mi
from
Marietta, GA
Click here to add this to my saved trials
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated:  12/31/1969
Retina Consultants of Nevada
mi
from
Las Vegas, NV
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Retina Consultants of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated:  12/31/1969
Mid Atlantic Retina - Wills Eye Hospital
mi
from
Cherry Hill, NJ
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Mid Atlantic Retina - Wills Eye Hospital
mi
from
Cherry Hill, NJ
Click here to add this to my saved trials
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated:  12/31/1969
Long Is. Vitreoretinal Consult
mi
from
Hauppauge, NY
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Long Is. Vitreoretinal Consult
mi
from
Hauppauge, NY
Click here to add this to my saved trials
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated:  12/31/1969
New Jersey Retina Research Foundation
mi
from
Edison, NJ
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
New Jersey Retina Research Foundation
mi
from
Edison, NJ
Click here to add this to my saved trials
Analyses of Existing Framingham Data
Continued Analyses of Epidemiologic Risk Factors Using Existing Framingham Eye and Heart Study Data
Status: Enrolling
Updated:  12/31/1969
National Eye Institute (NEI), 9000 Rockville Pike
mi
from
Bethesda, MD
Analyses of Existing Framingham Data
Continued Analyses of Epidemiologic Risk Factors Using Existing Framingham Eye and Heart Study Data
Status: Enrolling
Updated: 12/31/1969
National Eye Institute (NEI), 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Annular Array Ultrasound in Ophthalmology
High-frequency-ultrasound Annular Arrays for Ophthalmic Imaging
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center
mi
from
New York, NY
Annular Array Ultrasound in Ophthalmology
High-frequency-ultrasound Annular Arrays for Ophthalmic Imaging
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Clinical Outcomes Following Treatment With SYSTANE® BALANCE
Clinical Evaluation Following Use of SYSTANE® BALANCE in Subjects With Lipid-Deficient Dry Eye
Status: Enrolling
Updated:  12/31/1969
Contact Alcon Call Center for Trial Locations
mi
from
Fort Worth, TX
Clinical Outcomes Following Treatment With SYSTANE® BALANCE
Clinical Evaluation Following Use of SYSTANE® BALANCE in Subjects With Lipid-Deficient Dry Eye
Status: Enrolling
Updated: 12/31/1969
Contact Alcon Call Center for Trial Locations
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)
Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)
Status: Enrolling
Updated:  12/31/1969
Wilmer Eye Institute
mi
from
Baltimore, MD
Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)
Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)
Status: Enrolling
Updated: 12/31/1969
Wilmer Eye Institute
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Cornea & Cataract Consultants of Arizona
mi
from
Phoenix, AZ
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Cornea & Cataract Consultants of Arizona
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Schwartz Laser Eye Center
mi
from
Scottsdale, AZ
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Schwartz Laser Eye Center
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Eyecare Arkansas, P.A.
mi
from
Little Rock, AR
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Eyecare Arkansas, P.A.
mi
from
Little Rock, AR
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Little Rock Eye Clinic, LLP
mi
from
Little Rock, AR
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Little Rock Eye Clinic, LLP
mi
from
Little Rock, AR
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Sall Research Medical Center, Inc.
mi
from
Artesia, CA
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Sall Research Medical Center, Inc.
mi
from
Artesia, CA
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
United Medical Research Institute
mi
from
Inglewood, CA
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
United Medical Research Institute
mi
from
Inglewood, CA
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
North Valley Eye Medical Group, Inc.
mi
from
Mission Hills, CA
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
North Valley Eye Medical Group, Inc.
mi
from
Mission Hills, CA
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Montebello Medical Center, Inc.
mi
from
Montebello, CA
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Montebello Medical Center, Inc.
mi
from
Montebello, CA
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Pendleton Eye Center
mi
from
Oceanside, CA
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Pendleton Eye Center
mi
from
Oceanside, CA
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
North Bay Eye Associates
mi
from
Petaluma, CA
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
North Bay Eye Associates
mi
from
Petaluma, CA
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Martel Eye Medical Group
mi
from
Rancho Cordova, CA
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Martel Eye Medical Group
mi
from
Rancho Cordova, CA
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Sacramento Eye Consultants
mi
from
Sacramento, CA
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Sacramento Eye Consultants
mi
from
Sacramento, CA
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Eye Center of Northern Colorado
mi
from
Fort Collins, CO
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Eye Center of Northern Colorado
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Corneal Consultants of Colorado, P.C
mi
from
Littleton, CO
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Corneal Consultants of Colorado, P.C
mi
from
Littleton, CO
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Eye Center of Southern CT, P.C.
mi
from
Hamden, CT
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Eye Center of Southern CT, P.C.
mi
from
Hamden, CT
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Florida Eye Microsurgical Institute
mi
from
Boynton Beach, FL
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Florida Eye Microsurgical Institute
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Eye Associates of Fort Myers
mi
from
Fort Myers, FL
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Eye Associates of Fort Myers
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Atlantic Eye Center
mi
from
Palm Coast, FL
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Atlantic Eye Center
mi
from
Palm Coast, FL
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
The Eye Center of North Florida
mi
from
Panama City, FL
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
The Eye Center of North Florida
mi
from
Panama City, FL
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Dixon Eye Care
mi
from
Albany, GA
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Dixon Eye Care
mi
from
Albany, GA
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Jacksoneye, S. C.
mi
from
Lake Villa, IL
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Jacksoneye, S. C.
mi
from
Lake Villa, IL
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Midwest Cornea Associates, LLC
mi
from
Indianapolis, IN
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Midwest Cornea Associates, LLC
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Stiles Eyecare Excellence and Glaucoma Institute
mi
from
Overland Park, KA
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Stiles Eyecare Excellence and Glaucoma Institute
mi
from
Overland Park, KA
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Eye Research of Boston
mi
from
Winchester, MA
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Eye Research of Boston
mi
from
Winchester, MA
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Chu Vision Institute
mi
from
Bloomington, MN
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Chu Vision Institute
mi
from
Bloomington, MN
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Lifelong Vision Foundation at Pepose Vision Institute
mi
from
Chesterfield, MO
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Lifelong Vision Foundation at Pepose Vision Institute
mi
from
Chesterfield, MO
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Wellish Vision Institute
mi
from
Las Vegas, NV
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Wellish Vision Institute
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Matossian Eye Associates
mi
from
Pennington, NJ
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Matossian Eye Associates
mi
from
Pennington, NJ
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Rochester Ophthalmological Group
mi
from
Rochester, NY
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Rochester Ophthalmological Group
mi
from
Rochester, NY
Click here to add this to my saved trials
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated:  12/31/1969
Cornea Consultants of Albany
mi
from
Slingerlands, NY
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Cornea Consultants of Albany
mi
from
Slingerlands, NY
Click here to add this to my saved trials